Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus
Vaccination is the most effective preventive measure to control the spread of COVID-19 and reduce associated complications. This study aims to evaluate the efficacy and safety of mRNA COVID-19 vaccines in patients with systemic lupus erythematosus (SLE). A total of 41 adult SLE patients receiving tw...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/8/1221 |
| _version_ | 1797407554811199488 |
|---|---|
| author | Ilaria Mormile Francesca Della Casa Angelica Petraroli Alessandro Furno Francescopaolo Granata Giuseppe Portella Francesca Wanda Rossi Amato de Paulis |
| author_facet | Ilaria Mormile Francesca Della Casa Angelica Petraroli Alessandro Furno Francescopaolo Granata Giuseppe Portella Francesca Wanda Rossi Amato de Paulis |
| author_sort | Ilaria Mormile |
| collection | DOAJ |
| description | Vaccination is the most effective preventive measure to control the spread of COVID-19 and reduce associated complications. This study aims to evaluate the efficacy and safety of mRNA COVID-19 vaccines in patients with systemic lupus erythematosus (SLE). A total of 41 adult SLE patients receiving two doses of the SARS-CoV-2 mRNA Comirnaty-BioNTech/Pfizer vaccine were enrolled. The quantitative determination of anti-trimeric spike protein-specific IgG antibodies to SARS-CoV-2 was assessed before (T0), 21 days after the administration of the first dose of the vaccine (T1), and between 21 and 28 days after the second dose (T2). They were compared with the same determinations from a cohort of 29 patients with C1-esterase inhibitor deficiency hereditary angioedema (C1-INH-HAE) as controls. All the SLE patients and controls demonstrated a positive serological response after a single dose of the vaccine (T1), which significantly increased after the second dose (T2). No significant difference was found between SLE patients and controls at T1 [t(52.81) = −0.68; <i>p</i> = 0.49] and at T2 [t(67.74) = −0.22; <i>p</i> = 0.825]. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) analysis showed that the vaccine did not influence SLE activity or caused disease flare in our cohort. In conclusion, COVID-19 vaccines produced a satisfactory response in SLE patients without variation in the disease activity. |
| first_indexed | 2024-03-09T03:43:14Z |
| format | Article |
| id | doaj.art-34e1f14d0c404d02835cb3ef9f274c1b |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T03:43:14Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-34e1f14d0c404d02835cb3ef9f274c1b2023-12-03T14:36:43ZengMDPI AGVaccines2076-393X2022-07-01108122110.3390/vaccines10081221Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus ErythematosusIlaria Mormile0Francesca Della Casa1Angelica Petraroli2Alessandro Furno3Francescopaolo Granata4Giuseppe Portella5Francesca Wanda Rossi6Amato de Paulis7Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, ItalyDepartment of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, ItalyDepartment of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, ItalyDepartment of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, ItalyDepartment of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, ItalyDepartment of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, ItalyDepartment of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, ItalyDepartment of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, ItalyVaccination is the most effective preventive measure to control the spread of COVID-19 and reduce associated complications. This study aims to evaluate the efficacy and safety of mRNA COVID-19 vaccines in patients with systemic lupus erythematosus (SLE). A total of 41 adult SLE patients receiving two doses of the SARS-CoV-2 mRNA Comirnaty-BioNTech/Pfizer vaccine were enrolled. The quantitative determination of anti-trimeric spike protein-specific IgG antibodies to SARS-CoV-2 was assessed before (T0), 21 days after the administration of the first dose of the vaccine (T1), and between 21 and 28 days after the second dose (T2). They were compared with the same determinations from a cohort of 29 patients with C1-esterase inhibitor deficiency hereditary angioedema (C1-INH-HAE) as controls. All the SLE patients and controls demonstrated a positive serological response after a single dose of the vaccine (T1), which significantly increased after the second dose (T2). No significant difference was found between SLE patients and controls at T1 [t(52.81) = −0.68; <i>p</i> = 0.49] and at T2 [t(67.74) = −0.22; <i>p</i> = 0.825]. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) analysis showed that the vaccine did not influence SLE activity or caused disease flare in our cohort. In conclusion, COVID-19 vaccines produced a satisfactory response in SLE patients without variation in the disease activity.https://www.mdpi.com/2076-393X/10/8/1221anti-SARS-CoV-2 mRNA vaccinesCOVID-19SARS-CoV-2systemic lupus erythematosusvaccination |
| spellingShingle | Ilaria Mormile Francesca Della Casa Angelica Petraroli Alessandro Furno Francescopaolo Granata Giuseppe Portella Francesca Wanda Rossi Amato de Paulis Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus Vaccines anti-SARS-CoV-2 mRNA vaccines COVID-19 SARS-CoV-2 systemic lupus erythematosus vaccination |
| title | Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus |
| title_full | Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus |
| title_fullStr | Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus |
| title_full_unstemmed | Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus |
| title_short | Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus |
| title_sort | immunogenicity and safety of mrna anti sars cov 2 vaccines in patients with systemic lupus erythematosus |
| topic | anti-SARS-CoV-2 mRNA vaccines COVID-19 SARS-CoV-2 systemic lupus erythematosus vaccination |
| url | https://www.mdpi.com/2076-393X/10/8/1221 |
| work_keys_str_mv | AT ilariamormile immunogenicityandsafetyofmrnaantisarscov2vaccinesinpatientswithsystemiclupuserythematosus AT francescadellacasa immunogenicityandsafetyofmrnaantisarscov2vaccinesinpatientswithsystemiclupuserythematosus AT angelicapetraroli immunogenicityandsafetyofmrnaantisarscov2vaccinesinpatientswithsystemiclupuserythematosus AT alessandrofurno immunogenicityandsafetyofmrnaantisarscov2vaccinesinpatientswithsystemiclupuserythematosus AT francescopaologranata immunogenicityandsafetyofmrnaantisarscov2vaccinesinpatientswithsystemiclupuserythematosus AT giuseppeportella immunogenicityandsafetyofmrnaantisarscov2vaccinesinpatientswithsystemiclupuserythematosus AT francescawandarossi immunogenicityandsafetyofmrnaantisarscov2vaccinesinpatientswithsystemiclupuserythematosus AT amatodepaulis immunogenicityandsafetyofmrnaantisarscov2vaccinesinpatientswithsystemiclupuserythematosus |